These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16472049)

  • 21. High-sensitivity C-reactive protein in every chart? The use of biomarkers in individual patients.
    Ben-Yehuda O
    J Am Coll Cardiol; 2007 May; 49(21):2139-41. PubMed ID: 17531664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Statins and beyond: concurrent strategies for prevention of cardiovascular disease in patients with type 2 diabetes.
    Standl E
    Diab Vasc Dis Res; 2013 Mar; 10(2):99-114. PubMed ID: 22718811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of intensive risk factor management in type 2 diabetes on inflammatory biomarkers.
    Samaropoulos XF; Light L; Ambrosius WT; Marcovina SM; Probstfield J; Goff DC
    Diabetes Res Clin Pract; 2012 Mar; 95(3):389-98. PubMed ID: 22019270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: laboratory tests available to assess inflammation--performance and standardization: a background paper.
    Roberts WL; ;
    Circulation; 2004 Dec; 110(25):e572-6. PubMed ID: 15611384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma leptin concentration in patients with Type 2 diabetes: relationship to cardiovascular disease risk factors and insulin resistance.
    Abdella NA; Mojiminiyi OA; Moussa MA; Zaki M; Al Mohammedi H; Al Ozairi ES; Al Jebely S
    Diabet Med; 2005 Mar; 22(3):278-85. PubMed ID: 15717875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New American College of Cardiology and American Heart Association cholesterol treatment guidelines: subjects with Type 2 diabetes are under treated with high-intensity statins.
    Tripolt NJ; Sourij H
    Diabet Med; 2014 Jul; 31(7):879-80. PubMed ID: 24612178
    [No Abstract]   [Full Text] [Related]  

  • 27. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inflammation and type 2 diabetes.
    Calle MC; Fernandez ML
    Diabetes Metab; 2012 Jun; 38(3):183-91. PubMed ID: 22252015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How can we prevent cardiovascular disease in diabetes.
    Wiklund O; Håversen L; Pettersson C; Hultén LM
    J Intern Med; 2007 Aug; 262(2):199-207. PubMed ID: 17645587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-sensitivity C-reactive protein: a novel cardiovascular risk predictor in type 2 diabetics with normal lipid profile.
    Asegaonkar SB; Marathe A; Tekade ML; Cherekar L; Bavikar J; Bardapurkar J; Ajay R
    J Diabetes Complications; 2011; 25(6):368-70. PubMed ID: 22055258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diabetes and cardiovascular risk markers.
    Erdmann E
    Curr Med Res Opin; 2005; 21 Suppl 1():S21-8. PubMed ID: 15811196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations of plant sterols, lathosterol, oxidative stress and inflammatory markers after the combination therapy of ezetimibe and statin drugs in type 2 diabetic patients.
    Naruse R; Hori K; Terasawa T; Hara K; Suetsugu M; Takebayashi K; Morita K; Aso Y; Inukai T
    Obes Res Clin Pract; 2015; 9(1):67-74. PubMed ID: 25660177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
    Field KM
    Pharmacotherapy; 2005 Oct; 25(10):1365-77. PubMed ID: 16185181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
    Goff DC; Gerstein HC; Ginsberg HN; Cushman WC; Margolis KL; Byington RP; Buse JB; Genuth S; Probstfield JL; Simons-Morton DG;
    Am J Cardiol; 2007 Jun; 99(12A):4i-20i. PubMed ID: 17599424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C-reactive protein, antiinflammatory drugs, and quality of life in diabetes.
    Cummings DM; King DE; Mainous AG
    Ann Pharmacother; 2003 Nov; 37(11):1593-7. PubMed ID: 14565804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Inflammation and C-reactive protein in cardiovascular disease].
    Munk PS; Larsen AI
    Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular biomarkers in clinical studies of type 2 diabetes.
    Baldassarre MPA; Andersen A; Consoli A; Knop FK; Vilsbøll T
    Diabetes Obes Metab; 2018 Jun; 20(6):1350-1360. PubMed ID: 29419909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retinopathy and hypertension affect serum high-sensitivity C-reactive protein levels in Type 2 diabetic patients.
    Tsunoda K; Arita M; Yukawa M; Ueyama M; Furuta M; Nakagawa T; Nanjo K; Sanke T
    J Diabetes Complications; 2005; 19(3):123-7. PubMed ID: 15866055
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C-reactive protein: a novel marker of cardiovascular risk.
    Shah SH; Newby LK
    Cardiol Rev; 2003; 11(4):169-79. PubMed ID: 12852794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.